The positive Phase 2b data significantly de-risks the VCN-01 program and strengthens the company's position for partnerships, funding, or a potential acquisition. Traders should monitor for updates on the planned Phase 3 trial and any subsequent partnership announcements.
TOVX drugs
TOVX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 20 $0.4100entry
- T+1 · 7mo ago −17.07%α −16.42% · $0.3400
- T+5 · 7mo ago −14.63%α −15.55% · $0.3500
- T+20 · 6mo ago −26.83%α −31.03% · $0.3000
- T+60 · 4mo ago −40.76%α −47.53% · $0.2429
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Theriva Biologics announced positive results from its VIRAGE Phase 2b clinical trial, showing improved overall survival and progression-free survival in metastatic pancreatic cancer patients treated with VCN-01 plus chemotherapy. The data, to be presented at the AACR 2026 meeting, supports an immune-mediated mechanism of action and demonstrates consistent benefits across subgroups, including those with liver metastases.
Key Facts
- Patients receiving VCN-01 + chemotherapy had improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone.
- The survival benefit was maintained across subgroups, including patients with liver metastases.
- Patients who received a second dose of VCN-01 showed a greater benefit in OS and PFS.
- The company has achieved alignment with both the FDA and EMA on a proposed pivotal Phase 3 trial.
- The data presentation is scheduled for the AACR Annual Meeting on April 20, 2026.
Financial Impact
No direct financial figures provided, but the positive clinical data significantly increases the potential value of the VCN-01 program.
Risk Factors
- The data is from a Phase 2b trial and must be confirmed in a larger, pivotal Phase 3 study.
- The company is small (market cap $12M) and may face challenges in funding and executing the Phase 3 trial without a partnership.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-044906 |
| Document: tm2612012d1_ex99-1.htm | 0001104659-26-044906 |
| Document: tm2612012d1_ex99-2.htm | 0001104659-26-044906 |
| Document: 0001104659-26-044906-index-headers.html | 0001104659-26-044906 |
| Document: 0001104659-26-044906-index.html | 0001104659-26-044906 |
| Document: 0001104659-26-044906.txt | 0001104659-26-044906 |
Track record
11 reports on TOVX
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +17.39% at T+60 after the Aug 4, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.1600 to $0.1441 Now $0.1400 −12.50% ▼ −9.94% −9.57% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 Entry $0.1820 to $0.1900 Now $0.1400 −23.08% ▲ +4.40% +2.74% vs SPY
- Oct 20, 202627d ago DEF 14A Bearish 5/10 Entry $0.1966 to $0.1900 Now $0.1400 +28.79% ▲ +3.36% +2.18% vs SPY
- Aug 11, 202613w ago 8-K Neutral 4/10 No price data
- Aug 11, 202613w ago Press Release Neutral 5/10 Entry $0.2300 to $0.2400 Now $0.1400 −39.13% ▲ +4.35% +4.10% vs SPY
- Aug 4, 202614w ago 8-K Bearish 4/10 Entry $0.2300 to $0.2251 Now $0.1400 +39.13% ▲ +2.13% +1.93% vs SPY
- Jul 7, 202618w ago 8-K Bullish 5/10 Entry $0.2354 to $0.2378 Now $0.1400 −40.53% ▲ +1.02% +1.33% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $0.3070 to $0.3038 Now $0.1400 −54.40% ▼ −1.04% −1.58% vs SPY
- Apr 17, 202630w ago 8-K Bullish 7/10 Viewing Entry $0.4100 to $0.3400 Now $0.1400 −65.85% ▼ −17.07% −16.42% vs SPY
- Mar 12, 202635w ago 8-K Mixed 6/10 Entry $0.1800 to $0.1800 Now $0.1400 −22.22% · 0.00% +0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers